{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:57:31Z","timestamp":1751403451092,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Translational oncology research strives to explore a new aspect: identifying subgroups that exhibit treatment response even during pre-clinical phases. In this study, we focus on PDX models and their implementation in mouse clinical trials (MCT). Our primary objective was to identify subgroups with different treatment responses using Latent Class Mixed Model (LCMM).We used a public dataset and focused on one treatment, encorafenib, and two indications, melanoma and colorectal cancer, for which efficacy depends on a specific mutation BRAF V600E. One LCMM per indication was implemented to classify treatment responses at the PDX level, analyzing the growth kinetics of treated tumors and matched controls within the PDX models. A simulation study was carried out to explore the performance of LCMM in this context. For both applications, LCMM identified classes for which the higher the proportion of mutated BRAF V600E PDX models the greater the treatment effect, which is aligned with encorafenib use recommendations. The simulation study showed that LCMM could identify classes with large differences in treatment effects. LCMM is a suitable tool for MCT to explore treatment response subgroups of PDX. Once these subgroups are defined, characterization of their phenotypes\/genotypes could be performed to explore treatment response predictors.<\/jats:p>","DOI":"10.1038\/s41598-023-51055-7","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T23:01:51Z","timestamp":1704841311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Statistical classification of treatment responses in mouse clinical trials for stratified medicine in oncology drug discovery"],"prefix":"10.1038","volume":"14","author":[{"given":"H\u00e9l\u00e8ne","family":"Savel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Meyer-Losic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Proust-Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Richert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"51055_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11523-012-0237-6","volume":"7","author":"C Le Tourneau","year":"2012","unstructured":"Le Tourneau, C. et al. Designs and challenges for personalized medicine studies in oncology: Focus on the SHIVA trial. Target Oncol. 7, 253\u2013265 (2012).","journal-title":"Target Oncol."},{"key":"51055_CR2","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","volume":"29","author":"PJ O\u2019Dwyer","year":"2023","unstructured":"O\u2019Dwyer, P. J. et al. The NCI-MATCH trial: Lessons for precision oncology. Nat. Med. 29, 1349\u20131357 (2023).","journal-title":"Nat. Med."},{"key":"51055_CR3","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0748","author":"SC Huijberts","year":"2020","unstructured":"Huijberts, S. C., van Geel, R. M., Bernards, R., Beijnen, J. H. & Steeghs, N. Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer. Future Oncol. https:\/\/doi.org\/10.2217\/fon-2019-0748 (2020).","journal-title":"Future Oncol."},{"key":"51055_CR4","doi-asserted-by":"publisher","first-page":"175628482211106","DOI":"10.1177\/17562848221110644","volume":"15","author":"J Ros","year":"2022","unstructured":"Ros, J. et al. Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. Ther. Adv. Gastroenterol. 15, 17562848221110644 (2022).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"51055_CR5","doi-asserted-by":"publisher","first-page":"100795","DOI":"10.1016\/j.tranon.2020.100795","volume":"13","author":"G Roviello","year":"2020","unstructured":"Roviello, G. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. Transl. Oncol. 13, 100795 (2020).","journal-title":"Transl. Oncol."},{"key":"51055_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley, M. Encorafenib and binimetinib: First global approvals. Drugs 78, 1277\u20131284 (2018).","journal-title":"Drugs"},{"key":"51055_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/17512433.2019.1570847","volume":"12","author":"C Trojaniello","year":"2019","unstructured":"Trojaniello, C., Festino, L., Vanella, V. & Ascierto, P. A. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Rev. Clin. Pharmacol. 12, 259\u2013266 (2019).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"51055_CR8","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.esmoop.2020.100031","volume":"6","author":"A Trullas","year":"2021","unstructured":"Trullas, A. et al. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. ESMO Open 6, 100031 (2021).","journal-title":"ESMO Open"},{"key":"51055_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12967-021-02910-6","volume":"19","author":"D Hartl","year":"2021","unstructured":"Hartl, D. et al. Translational precision medicine: An industry perspective. J. Transl. Med. 19, 245 (2021).","journal-title":"J. Transl. Med."},{"key":"51055_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12885-019-5907-7","volume":"19","author":"S Guo","year":"2019","unstructured":"Guo, S., Jiang, X., Mao, B. & Li, Q.-X. The design, analysis and application of mouse clinical trials in oncology drug development. BMC Cancer 19, 718 (2019).","journal-title":"BMC Cancer"},{"key":"51055_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2017.307","volume":"50","author":"J Jung","year":"2018","unstructured":"Jung, J., Seol, H. S. & Chang, S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res. Treat. 50, 1\u201310 (2018).","journal-title":"Cancer Res. Treat."},{"key":"51055_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318\u20131325 (2015).","journal-title":"Nat. Med."},{"key":"51055_CR13","doi-asserted-by":"publisher","first-page":"30723","DOI":"10.1038\/srep30723","volume":"6","author":"TD Laajala","year":"2016","unstructured":"Laajala, T. D. et al. Optimized design and analysis of preclinical intervention studies in vivo. Sci. Rep. 6, 30723 (2016).","journal-title":"Sci. Rep."},{"key":"51055_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.18637\/jss.v078.i02","volume":"78","author":"C Proust-Lima","year":"2017","unstructured":"Proust-Lima, C., Philipps, V. & Liquet, B. Estimation of extended mixed models using latent classes and latent processes: The R package lcmm. J. Stat. Softw. 78, 25 (2017).","journal-title":"J. Stat. Softw."},{"key":"51055_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1158\/2767-9764.CRC-22-0238","volume":"3","author":"H Savel","year":"2023","unstructured":"Savel, H. et al. On the choice of longitudinal models for the analysis of antitumor efficacy in mouse clinical trials of patient-derived xenograft models. Cancer Res. Commun. 3, 140\u2013147 (2023).","journal-title":"Cancer Res. Commun."},{"key":"51055_CR16","volume-title":"M\u00e9thodes Biostatistiques Appliqu\u00e9es \u00e0 la Recherche Clinique en Canc\u00e9rologie, Vol 2","author":"S Gourgou","year":"2021","unstructured":"Gourgou, S., Paoletti, X. & Mathoulin-P\u00e9lissier, S. M\u00e9thodes Biostatistiques Appliqu\u00e9es \u00e0 la Recherche Clinique en Canc\u00e9rologie, Vol 2 (John Libbey Eurotext, 2021)."},{"key":"51055_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.therap.2022.11.011","volume":"78","author":"M Roustit","year":"2023","unstructured":"Roustit, M. et al. Les essais plateformes. Therapie 78, 19\u201328 (2023).","journal-title":"Therapie"},{"key":"51055_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamaoncol.2016.5299","volume":"3","author":"HJ West","year":"2017","unstructured":"West, H. J. Novel precision medicine trial designs: Umbrellas and baskets. JAMA Oncol. 3, 423\u2013423 (2017).","journal-title":"JAMA Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-51055-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-51055-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-51055-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T23:01:59Z","timestamp":1704841319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-51055-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51055"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-51055-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HS and FML: Ipsen employees; CPL and LR: the authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"934"}}